Literature DB >> 9667556

Hypothesis on the pathogenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS.

S V Tan1, R J Guiloff.   

Abstract

Certain aspects of the clinical syndrome of dementia, cerebral atrophy, predominantly sensory neuropathy, and vacuolar myelopathy in AIDS resemble those seen in vitamin B12 deficiency. Pathologically, there are similarities not only in the changes in the spinal cord, but also in the brain and peripheral nerves. The pathogenesis of vacuolar myelopathy may be secondary to a combination of immune mediated myelin and oligodendrocyte injury, and simultaneous impairment of repair mechanisms due to a deficiency of S-adenosylmethionine (SAM). Products derived from macrophages may interfere directly with the methyl transfer cycle through the generation of reactive oxygen intermediates and reactions involving nitric oxide and peroxynitrite which may limit the supply of methionine for conversion to SAM, both by direct interaction as well as through inhibition of methionine synthase. Macrophage activation with secretion of cytokines and other biologically reactive substances within the nervous system is sustained in the late stages of HIV infection by the general effects of immune depletion, including loss of T cells (with concomitant reduction of macrophage regulatory molecules) and recurrent opportunistic infections, and may be further augmented by the local presence of the virus itself (or its surface glycoprotein gp120). This would account for the common, but not exclusive, occurrence of vacuolar myelopathy in AIDS. The ability of the virus and its products to stimulate macrophage and microglial activation may also explain the association between severity of vacuolar myelopathy and the presence of HIV encephalitis. A similar mechanism may underlie the pathogenesis of dementia, cerebral atrophy, and peripheral neuropathy. Local factors or differential susceptibility between the central and peripheral nervous system may determine whether myelinotoxic or neurotoxic processes predominate; the prominence of myelin involvement in the spinal cord, and axonal involvement peripherally may reflect both ends of this range, with the brain manifesting a more equal balance of both processes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9667556      PMCID: PMC2170156          DOI: 10.1136/jnnp.65.1.23

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  72 in total

1.  Subacute combined degeneration of the spinal cord; current concepts of the disease process; value of serum vitamin B12; determinations in clarifying some of the common clinical problems.

Authors:  M VICTOR; A A LEAR
Journal:  Am J Med       Date:  1956-06       Impact factor: 4.965

2.  AIDS-associated vacuolar myelopathy. A morphometric study.

Authors:  S V Tan; R J Guiloff; F Scaravilli
Journal:  Brain       Date:  1995-10       Impact factor: 13.501

3.  Human immunodeficiency virus type 1 expression in the central nervous system correlates directly with extent of disease.

Authors:  B Weiser; N Peress; D La Neve; D J Eilbott; R Seidman; H Burger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

4.  Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide.

Authors:  R Radi; J S Beckman; K M Bush; B A Freeman
Journal:  J Biol Chem       Date:  1991-03-05       Impact factor: 5.157

5.  Vacuolar myelopathy in transgenic mice expressing human immunodeficiency virus type 1 proteins under the regulation of the myelin basic protein gene promoter.

Authors:  G Goudreau; S Carpenter; N Beaulieu; P Jolicoeur
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

Review 6.  Nitric oxide and neurons.

Authors:  S H Snyder
Journal:  Curr Opin Neurobiol       Date:  1992-06       Impact factor: 6.627

7.  Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status.

Authors:  M P Heyes; B J Brew; A Martin; R W Price; A M Salazar; J J Sidtis; J A Yergey; M M Mouradian; A E Sadler; J Keilp
Journal:  Ann Neurol       Date:  1991-02       Impact factor: 10.422

8.  AIDS-associated vacuolar myelopathy and tumor necrosis factor-alpha (TNF alpha).

Authors:  S V Tan; R J Guiloff; D C Henderson; B G Gazzard; R Miller
Journal:  J Neurol Sci       Date:  1996-06       Impact factor: 3.181

9.  Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection: effect of parenteral treatment with SAMe.

Authors:  A Castagna; C Le Grazie; A Accordini; P Giulidori; G Cavalli; T Bottiglieri; A Lazzarin
Journal:  Neurology       Date:  1995-09       Impact factor: 9.910

10.  Axonal atrophy in the painful peripheral neuropathy in AIDS.

Authors:  G N Fuller; J M Jacobs; R J Guiloff
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

View more
  5 in total

1.  HIV-Associated Vacuolar Encephalomyelopathy.

Authors:  Gregory R Madden; Molly E Fleece; Akriti Gupta; M Beatriz S Lopes; Scott K Heysell; Christopher J Arnold; Brian Wispelwey
Journal:  Open Forum Infect Dis       Date:  2019-10-01       Impact factor: 3.835

Review 2.  Neurologic presentations of AIDS.

Authors:  Elyse J Singer; Miguel Valdes-Sueiras; Deborah Commins; Andrew Levine
Journal:  Neurol Clin       Date:  2010-02       Impact factor: 3.806

3.  Diffusion tensor MR imaging (DTI) metrics in the cervical spinal cord in asymptomatic HIV-positive patients.

Authors:  Christina Mueller-Mang; Meng Law; Thomas Mang; Julia Fruehwald-Pallamar; Michael Weber; Majda M Thurnher
Journal:  Neuroradiology       Date:  2010-11-03       Impact factor: 2.804

4.  Atypical HIV-vacuolar myelopathy: a case report.

Authors:  Tau Mongezi; Joseph Sibi; George Jerry; Ibañez-Valdés Lourdes de Fátima; Dubula Tozama; Foyaca Sibat Humberto
Journal:  Eur J Med Res       Date:  2021-02-01       Impact factor: 2.175

5.  Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection.

Authors:  Erika Ahlgren; Lars Hagberg; Dietmar Fuchs; Lars-Magnus Andersson; Staffan Nilsson; Henrik Zetterberg; Magnus Gisslén
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.